Sight Sciences

Sight Sciences company information, Employees & Contact Information

Explore related pages

Related company profiles:

We are reimagining eyecare with transformative technology and an interventional mindset. We believe interventions should happen sooner to preserve, protect, or restore natural eye function. So, we aim to provide eyecare providers with transformative, clinically-proven therapies that are intuitive, less invasive, and more intelligent.

Company Details

Employees
236
Founded
-
Address
4040 Campbell Ave,
Industry
Medical Equipment Manufacturing
NAICS
Medical Equipment and Supplies Manufacturing
Surgical and Medical Instrument Manufacturing
Surgical Appliance and Supplies Manufacturing
Dental Equipment and Supplies Manufacturing
Ophthalmic Goods Manufacturing
Dental Laboratories
HQ
Menlo Park, California
Looking for a particular Sight Sciences employee's phone or email?

Sight Sciences Questions

News

Sight Sciences to Report Third Quarter 2025 Financial Results on November 6, 2025 - GlobeNewswire

Sight Sciences to Report Third Quarter 2025 Financial Results on November 6, 2025 GlobeNewswire

Sight Sciences, Inc. to Report Q3 2025 Financial Results on November 6, 2025 - Quiver Quantitative

Sight Sciences, Inc. to Report Q3 2025 Financial Results on November 6, 2025 Quiver Quantitative

Sight Sciences (Nasdaq: SGHT) sets earnings call on Nov. 6 after market close - Stock Titan

Sight Sciences (Nasdaq: SGHT) sets earnings call on Nov. 6 after market close Stock Titan

Sight Sciences Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance - Yahoo Finance

Sight Sciences Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance Yahoo Finance

30 Million UnitedHealthcare Members Gain Access: Sight Sciences' OMNI System Approved for Glaucoma Treatment - Stock Titan

30 Million UnitedHealthcare Members Gain Access: Sight Sciences' OMNI System Approved for Glaucoma Treatment Stock Titan

Sight Sciences releases cost-utility analysis comparing TearCare and cyclosporine 0.05% in dry eye - Ophthalmology Times

Sight Sciences releases cost-utility analysis comparing TearCare and cyclosporine 0.05% in dry eye Ophthalmology Times

Sight Sciences Debuts OMNI Edge Surgical System - VisionMonday

Sight Sciences Debuts OMNI Edge Surgical System VisionMonday

Sight Sciences Announces Fee Schedule Establishment from - GlobeNewswire

Sight Sciences Announces Fee Schedule Establishment from GlobeNewswire

Exclusive: Sight Sciences to Unveil Latest Eye Care Innovation Strategy at Major Citi Conference - Stock Titan

Exclusive: Sight Sciences to Unveil Latest Eye Care Innovation Strategy at Major Citi Conference Stock Titan

Sight Sciences Announces Medicare Pricing for TearCare® Procedure in Novitas and First Coast Jurisdictions - Quiver Quantitative

Sight Sciences Announces Medicare Pricing for TearCare® Procedure in Novitas and First Coast Jurisdictions Quiver Quantitative

Sight Sciences Announces the OMNI® Surgical System to be - GlobeNewswire

Sight Sciences Announces the OMNI® Surgical System to be GlobeNewswire

Sight Sciences Announces Cost Savings Findings from TearCare® System Budget Impact Analysis for Dry Eye Disease Treatment - Quiver Quantitative

Sight Sciences Announces Cost Savings Findings from TearCare® System Budget Impact Analysis for Dry Eye Disease Treatment Quiver Quantitative

Sight Sciences to Debut OMNI® Edge Surgical System at the - GlobeNewswire

Sight Sciences to Debut OMNI® Edge Surgical System at the GlobeNewswire

Sight Sciences to Host Surgical Glaucoma Investor Symposium on Friday, May 5, 2023 - Yahoo Finance

Sight Sciences to Host Surgical Glaucoma Investor Symposium on Friday, May 5, 2023 Yahoo Finance

Sight Sciences Announces Successful $34 Million Patent - GlobeNewswire

Sight Sciences Announces Successful $34 Million Patent GlobeNewswire

Sight Sciences Reports First Quarter 2023 Financial Results and Reaffirms Guidance for Full Year 2023 - Yahoo Finance

Sight Sciences Reports First Quarter 2023 Financial Results and Reaffirms Guidance for Full Year 2023 Yahoo Finance

89% Treatment Success: Sight Sciences' OMNI System Proves Superior for Glaucoma in Major Meta-Analysis - Stock Titan

89% Treatment Success: Sight Sciences' OMNI System Proves Superior for Glaucoma in Major Meta-Analysis Stock Titan

Sight Sciences Announces 1,000th TearCare® Customer Installation - Yahoo Finance

Sight Sciences Announces 1,000th TearCare® Customer Installation Yahoo Finance

10.4M covered lives: Sight Sciences wins jurisdiction-wide Medicare fee for CPT 0563T with Jan 1, 2025 effective date - Stock Titan

10.4M covered lives: Sight Sciences wins jurisdiction-wide Medicare fee for CPT 0563T with Jan 1, 2025 effective date Stock Titan

Sight Sciences Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial Results - Yahoo Finance

Sight Sciences Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial Results Yahoo Finance

Sight Sciences Announces Substantial Crossover Raise - PR Newswire

Sight Sciences Announces Substantial Crossover Raise PR Newswire

Sight Sciences Raises $56M of Growth Capital to Lead the Development of the Standalone MIGS Market and Procedure-Based Dry Eye Market - PR Newswire

Sight Sciences Raises $56M of Growth Capital to Lead the Development of the Standalone MIGS Market and Procedure-Based Dry Eye Market PR Newswire

Sight Sciences' OMNI System Shows Breakthrough 3-Year Success in Landmark Glaucoma Study - Stock Titan

Sight Sciences' OMNI System Shows Breakthrough 3-Year Success in Landmark Glaucoma Study Stock Titan

TearCare superior to Restasis in TBUT, measures of meibomian gland secretion in dry eye - Healio

TearCare superior to Restasis in TBUT, measures of meibomian gland secretion in dry eye Healio

Sight Sciences Announces $30 Million Financing Led by D1 Capital Partners - PR Newswire

Sight Sciences Announces $30 Million Financing Led by D1 Capital Partners PR Newswire

Sight Sciences Introduces the SION™ Surgical Instrument – The First Bladeless Device Used in Goniotomy - GlobeNewswire

Sight Sciences Introduces the SION™ Surgical Instrument – The First Bladeless Device Used in Goniotomy GlobeNewswire

Sight Sciences Hires Leading Industry Executives to Drive Continued Growth - PR Newswire

Sight Sciences Hires Leading Industry Executives to Drive Continued Growth PR Newswire

Sight Sciences (SGHT) Stock Price, News & Analysis - MarketBeat

Sight Sciences (SGHT) Stock Price, News & Analysis MarketBeat

SGHT Stock Price and Chart — NASDAQ:SGHT - TradingView

SGHT Stock Price and Chart — NASDAQ:SGHT TradingView

Sight Sciences Announces Official Launches of TearCare® and the Enhanced, Next Generation OMNI® System - PR Newswire

Sight Sciences Announces Official Launches of TearCare® and the Enhanced, Next Generation OMNI® System PR Newswire

Top Sight Sciences Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant